CoinShares (CSHR) Q2 2026 Earnings Call Transcript

CoinShares reported H1 2026 revenue of $51.4 million, down 35.7% year over year, and a $23.9 million net loss as Bitcoin and Ethereum fell roughly 32% and 48%, respectively. AUM declined from $7.4 billion at year-end to $5.5 billion, though the company generated $27.6 million of net inflows, including $155.9 million into its CoinShares Physical platform. Segment EBITDA remained positive at $21.6 million, while the company repaid all $28.3 million of long-term debt and ended June with $413.9 million of available capital; AUM subsequently recovered 25% to $6.9 billion by August 31. The board proposed authorization to repurchase up to 32.9 million shares, or 25% of shares outstanding, citing a valuation below perceived business value.

Analysis

CSHR is effectively a high-beta, fee-sensitive crypto-asset manager whose earnings torque is larger than its headline AUM recovery suggests: rising crypto prices also rotate assets back toward materially higher-yield products. The key underwriting issue is whether that mix reversal is durable; an AUM rebound driven only by price appreciation lifts revenue quickly, but does not establish distribution-market-share gains. Physical-platform flow momentum is the cleaner leading indicator, while legacy-product attrition remains a structural drag.

The balance-sheet discount is potentially real but overstated if accrued digital-asset fees are treated as cash-equivalent. Their conversion depends on product-redemption behavior and crypto liquidity, while treasury marks and the XBT liability hedge can continue to create accounting volatility that investors may not fully ignore. A buyback authorization is a valuation support mechanism rather than an executed catalyst; with liquid cash below the maximum authorization's implied cost, aggressive repurchases would compete directly with M&A, seed capital, and countercyclical trading opportunities.

Near term, CSHR should trade primarily on BTC/ETH and evidence that the higher-fee AUM mix persists into quarter-end. Over 1-3 months, executed buybacks, Russell eligibility confirmation, and stronger U.S. liquidity could narrow the holding-company discount. Over 6-18 months, fee compression is the larger risk: European physical ETP and UCITS growth expands distribution but likely lowers take rates unless active strategies achieve scale; this is also a modest negative read-through for IVZ's low-fee indexed-product economics, though immaterial to its consolidated earnings.

Contrarian view: the market may be valuing CSHR as a crypto proxy rather than a capital allocator with balance-sheet optionality. That optionality deserves a discount until management proves disciplined deployment and cash realization; a renewed crypto drawdown would expose fixed-cost leverage and likely prevent buyback execution when it is most needed.

Key Decisions for Investors

• Watch, do not initiate NDAQ or IVZ on this event: CoinShares' U.S. listing and European product activity are far too small to affect either firm's earnings; reassess only if NDAQ reports material new-listing or crypto-ETP trading-volume traction.
• For crypto exposure, consider a tactical long CSHR only after confirmation that August AUM momentum holds through quarter-end and buybacks are actually initiated. Target a 3-6 month rerating from executed capital returns plus higher fee mix; exit if AUM falls below the June trough or high-fee products revert below 40% of AUM.
• Structure CSHR exposure as a paired long versus a liquid crypto-beta proxy rather than outright where possible: the intended alpha is discount closure and operating-mix improvement, not BTC direction. Avoid the trade if management commits to a cash-funded acquisition before demonstrating purchase discipline.
• Set a diligence alert on the ratio of liquid cash to accrued fee assets and on XBT pricing-differential volatility. A further large adverse accounting swing, material legacy outflows, or lower product-level fees—not merely lower blended yield—would falsify the resilience thesis.